Publicaciones en las que colabora con Jordi Vila Estapé (27)

2024

  1. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 69-77

  2. In vitro activity of ozenoxacin against Staphylococcus aureus and Streptococcus pyogenes clinical isolates recovered in a worldwide multicentre study (2020-2022)

    JAC-Antimicrobial Resistance, Vol. 6, Núm. 3

2023

  1. Corrigendum: CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3(Front. Microbiol., (2022), 13, (918362), 10.3389/fmicb.2022.918362)

    Frontiers in Microbiology

  2. Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action

    World Journal of Emergency Surgery, Vol. 18, Núm. 1

2022

  1. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

    Frontiers in Microbiology, Vol. 13

  2. Hidden dissemination of carbapenem-susceptible OXA-48-producing Proteus mirabilis

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3009-3015

2021

  1. Uptake of ozenoxacin and other quinolones in gram-positive bacteria

    International Journal of Molecular Sciences, Vol. 22, Núm. 24

2020

  1. Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA

    International Journal of Antimicrobial Agents, Vol. 56, Núm. 3

2019

  1. Microbiological profile of ozenoxacin

    Future Microbiology, Vol. 14, Núm. 9, pp. 773-787

  2. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or - resistant Staphylococcus aureus and Staphylococcus epidermidis

    PLoS ONE, Vol. 14, Núm. 10

  3. Ozenoxacin: a review of preclinical and clinical efficacy

    Expert Review of Anti-Infective Therapy, Vol. 17, Núm. 3, pp. 159-168

2018

  1. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain

    International Journal of Antimicrobial Agents, Vol. 51, Núm. 3, pp. 511-515

  2. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates

    Future Microbiology, Vol. 13, Núm. 6s, pp. 3-19

2016

  1. Escherichia coli: An old friend with new tidings

    FEMS Microbiology Reviews, Vol. 40, Núm. 4, pp. 437-463

2015

  1. Evaluation of the eazyplex® SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 4, pp. 1047-1050

  2. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 1, pp. 57-61

  3. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 8, pp. 2306-2310

2014

  1. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

    Journal of Hepatology

  2. Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values

    Diagnostic Microbiology and Infectious Disease, Vol. 78, Núm. 3, pp. 263-267

2013

  1. In vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria

    Antimicrobial Agents and Chemotherapy, Vol. 57, Núm. 12, pp. 6389-6392